title: Pemetrexed-induced pneumonitis: a case report.
abstract: Pemetrexed is a structurally novel antifolate agent approved in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma who have unresectable disease and for the therapy of previously treated patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) as a single agent or in association with cisplatin as a first-line treatment in patients with nonsquamous histology. Herein, we report a case of pemetrexed-induced pneumonitis. Because pemetrexed is being prescribed with increasing frequency for NSCLC and mesothelioma, we believe that physicians should be aware of this rare but serious complication.
authors.affiliation: Department of Medicine, SITEP, Institut Gustave Roussy, Universite Paris XI, and Department of Pneumology, Hôpital Tenon, Marie Curie, Paris VI, France.
authors.forename: Yohann
authors.initials: Y
authors.lastname: Loriot
authors.forename: Charles
authors.initials: C
authors.lastname: Ferte
authors.forename: Carlos
authors.initials: C
authors.lastname: Gomez-Roca
authors.forename: Christian
authors.initials: C
authors.lastname: Moldovan
authors.forename: Ratislav
authors.initials: R
authors.lastname: Bahleda
authors.forename: Marie
authors.initials: M
authors.lastname: Wislez
authors.forename: Jacques
authors.initials: J
authors.lastname: Cadranel
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D002939:Ciprofloxacin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004417:Dyspnea; D004890:Erythema; D005971:Glutamates / Q000008:administration & dosage / Q000009:adverse effects; D006147:Guanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009364:Neoplasm Recurrence, Local; D017239:Paclitaxel / Q000008:administration & dosage; D000068437:Pemetrexed; D011014:Pneumonia / Q000139:chemically induced / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology; D011658:Pulmonary Fibrosis; D020127:Recovery of Function; D003074:Solitary Pulmonary Nodule / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
chemical_list: D000305:Adrenal Cortex Hormones; D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D005971:Glutamates; D000068437:Pemetrexed; D002939:Ciprofloxacin; D006147:Guanine; D017239:Paclitaxel; D002945:Cisplatin